Cardiology

High-level results show the trial met its composite primary endpoint, lowering risk of CV death or worsening disease in patients with HFmrEF/HFpEF.

Black patients hospitalized with atrial fibrillation were 25% less likely to receive oral anticoagulants upon discharge according to a large national registry study.

PCPs and internists accounted nationally for 57% of SGLT2i and 52% of GLP1RA prescriptions in 2020, more than any other specialty, according to new research.

The cardiac myosin inhibitor is the only treatment that targets the pathophysiology of the disease, improving patient function and symptoms.

USPSTF states low-dose aspirin should be considered for CVD prevention on a case-by-case basis in adults aged 40-59 yrs with a 10% or greater 10-year CVD risk.

Dylan Steen, MD talks about several SuperWIN results that caught him happily by surprise and suggest plenty of room for follow-up research.

NAFLD is a key risk factor for ASCVD and widely underdiagnosed. This Guideline Topline summarizes new AHA warnings, guidance.

Researchers developed polygenic risk scores for 6 common diseases and informational resources to help primary care physicians incorporate them into clinical practice.

The NDA for daprodustat, a novel investigational agent, is based on data from pivotal ASCEND program clinical trials.

Patients who received a low-dose 3-drug combination pill achieved time at BP target of 64% vs the usual care group result of 43% in a post-hoc analysis of TRIUMPH.

SuperWIN trial findings suggest the future of successful health care depends on harnessing familiar, community- based resources to maintain health and deliver care.

Coprincipal investigator Steen highlights the first-of-its kind study and the findings—local in-store dietitian counseling/feedback, nutrition education, and online shopping savvy improve food choices, health metrics.

Obesity significantly increased the risk of heart failure among women who experienced menopause at age ≥55 years in a new study.

Persons with ASCVD who quit smoking could gain 5 more years of life--similar to the outcome of intensive medical treatment while continuing to smoke.

The FDA clearance for the FitBit algorithm will provide another widely tested tool for patient and clinicians to help identify arrhythmias earlier and avoid severe cardiocerebrovascular events.

ACC 2022: Use of antihypertensive therapy in pregnant women was associated with better pregnancy outcomes, such as preeclampsia and fetal or neonatal death.

In patients with type 2 diabetes and chronic kidney disease with and without history of CVD, finerenone was associated with improved CV and kidney outcomes.

The new HF guidelines prioritize primary prevention, revise disease stages to encourage early intervention, and now include SGLT2i as guideline-directed medical therapy.

ACC 2022: Updated findings further highlight benefit of sotagliflozin treatment in patients with T2D and CKD, regardless of cardiovascular disease presence.

ACC 2022. An EHR alert tailored to prompt clinicians to check guideline-directed medical therapy for individual HF patients was integrated carefully into clinical workflow.

ACC 2022. SODIUM-HF secondary findings, however, showed improvement in NYHA HF class and in QOL in the dietary intervention group.

ACC 2022. Findings suggest that more attention to monitoring cognitive functioning after a myocardial infarction is needed.

ACC 2022. Study assessed hypertension-related TikTok videos and found that 42% addressed alternative medicine, more than twice the number that focused on medical treatments.

ACC 2022. Black and Hispanic persons were 41% less likely than white individuals to receive CPR after cardiac arrest in public and 26% less likely when the event occurred in their home.

The higher dose of the GLP-1 analogue allows more flexibility for patients with T2D needing to intensify treatment, says manufacturer Novo Nordisk.

ACC 2022. Can a couple of cups of coffee per day keep cardiovascular disease at bay? Findings from 3 new studies shed light.

ACC 2022. Approximately 5% of hospitalizations for acute MI in the state were found attributable to elevated levels of traffic noise.

ACC 2022. ACC late-breaking clinical trial sessions begin Sat, April 2, 2022. Our short slide shows highlight the studies of interest to primary care clinicians.

At ACC 2022 on Sunday, 4-2, look for studies on icosapent ethyl and alirocumab, landmark research on HFrEF, and a novel anticoagulant for atrial fibrillation.

At ACC 2022 on Sunday, 4-2, look for studies on icosapent ethyl and alirocumab, landmark research on HFrEF, and a novel anticoagulant for atrial fibrillation.